At a glance
ClinicalIndex Comparison RecordN/ACompleted· 267 enrolled
Drug / intervention
TIGRIS Vascular Stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
In Brief
A clinical study evaluating TIGRIS Vascular Stent and BARD LifeStent for Peripheral Arterial Disease. Completed, enrolled 267 participants across 34 sites.
Detailed Summary
The primary objective of the randomized study is to evaluate the safety and effectiveness of the TIGRIS Vascular Stent in the treatment of de novo and restenotic atherosclerotic lesions, ≤ 24cm in length, in the superficial femoral and proximal popliteal arteries (SFA/PPA) of patients with symptomatic peripheral arterial disease (PAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
First PostedApr 2012
Primary CompletionAug 2015
Study CompletionAug 2017
TodayJul 2026
First PostedApr 12, 2012
Enrollment StartApr 1, 2012
Primary CompletionAug 1, 2015
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.2 years ago
Interventions
TIGRIS Vascular Stentdevice
Implant
BARD LifeStentdevice
Implant